{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:38:11Z","timestamp":1788885491484,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T00:00:00Z","timestamp":1433548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81200600"],"award-info":[{"award-number":["81200600"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2013FJ4236"],"award-info":[{"award-number":["2013FJ4236"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12933-015-0229-9","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T06:52:48Z","timestamp":1433487168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes"],"prefix":"10.1186","volume":"14","author":[{"given":"Yang","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofeng","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,6]]},"reference":[{"issue":"2","key":"229_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jb\/mvq121","volume":"149","author":"N Itoh","year":"2011","unstructured":"Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011;149(2):121\u201330.","journal-title":"J Biochem"},{"issue":"1","key":"229_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/dvdy.21388","volume":"237","author":"N Itoh","year":"2008","unstructured":"Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn. 2008;237(1):18\u201327.","journal-title":"Dev Dyn"},{"issue":"2","key":"229_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1210\/en.2006-1168","volume":"148","author":"A Kharitonenkov","year":"2007","unstructured":"Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148(2):774\u201381.","journal-title":"Endocrinology"},{"issue":"6","key":"229_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627\u201335.","journal-title":"J Clin Invest"},{"issue":"3","key":"229_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","volume":"71","author":"M Mraz","year":"2009","unstructured":"Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71(3):369\u201375.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"229_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246\u201353.","journal-title":"Diabetes"},{"issue":"8","key":"229_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"229_CR8","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1210\/jc.2011-1930","volume":"97","author":"Y Xiao","year":"2012","unstructured":"Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab. 2012;97(1):E54\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"229_CR9","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1210\/jc.2008-2331","volume":"94","author":"H Li","year":"2009","unstructured":"Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009;94(6):2151\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"229_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","volume":"40","author":"Y Yilmaz","year":"2010","unstructured":"Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010;40(10):887\u201392.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"229_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","volume":"53","author":"H Li","year":"2010","unstructured":"Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53(5):934\u201340.","journal-title":"J Hepatol"},{"issue":"11","key":"229_CR12","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781\u20139.","journal-title":"Diabetes"},{"issue":"12","key":"229_CR13","doi-asserted-by":"publisher","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","volume":"5","author":"Z Lin","year":"2010","unstructured":"Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010;5(12):e15534.","journal-title":"PLoS One"},{"key":"229_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1475-2840-12-124","volume":"12","author":"Y Shen","year":"2013","unstructured":"Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013;12:124.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"229_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","volume":"33","author":"WS Chow","year":"2013","unstructured":"Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33(10):2454\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"229_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.diabres.2012.01.004","volume":"96","author":"SY An","year":"2012","unstructured":"An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012;96(2):196\u2013203.","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 1","key":"229_CR17","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.2337\/dc07-S042","volume":"30","author":"American Diabetes Association","year":"2007","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30 Suppl 1:S42\u20137.","journal-title":"Diabetes Care"},{"issue":"19","key":"229_CR18","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection E","year":"2001","unstructured":"Expert Panel on Detection E. Treatment of high blood cholesterol in a: executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama. 2001;285(19):2486\u201397.","journal-title":"Jama"},{"issue":"3","key":"229_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/01.ATV.0000201289.83256.cf","volume":"26","author":"I Kardys","year":"2006","unstructured":"Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006;26(3):631\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"229_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/000331970005100401","volume":"51","author":"A Balbarini","year":"2000","unstructured":"Balbarini A, Buttitta F, Limbruno U, Petronio AS, Baglini R, Strata G, et al. Usefulness of carotid intima-media thickness measurement and peripheral B-mode ultrasound scan in the clinical screening of patients with coronary artery disease. Angiology. 2000;51(4):269\u201379.","journal-title":"Angiology"},{"key":"229_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-014-0107-x","volume":"13","author":"J Liang","year":"2014","unstructured":"Liang J, Wang Y, Li H, Liu X, Qiu Q, Qi L. Neck circumference and early stage atherosclerosis: the cardiometabolic risk in Chinese (CRC) study. Cardiovasc Diabetol. 2014;13:107.","journal-title":"Cardiovasc Diabetol"},{"key":"229_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12933-014-0141-8","volume":"13","author":"A Lukich","year":"2014","unstructured":"Lukich A, Gavish D, Shargorodsky M. Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health. Cardiovasc Diabetol. 2014;13:141.","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"229_CR23","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","volume":"285","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285(19):2481\u20135.","journal-title":"JAMA"},{"issue":"2","key":"229_CR24","first-page":"BC23","volume":"9","author":"RK Reddy","year":"2015","unstructured":"Reddy RK, Mahendra J, Gurumurthy P, Jayamathi Babu S. Identification of predictable biomarkers in conjunction to Framingham risk score to predict the risk for cardiovascular disease (CVD) in Non cardiac subjects. J Clin Diagn Res. 2015;9(2):BC23\u20137.","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"229_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2265.2011.04078.x","volume":"75","author":"SJ Yang","year":"2011","unstructured":"Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, et al. Effects of a 3\u00a0month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011;75(4):464\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"229_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.diabres.2013.04.010","volume":"101","author":"M Lenart-Lipinska","year":"2013","unstructured":"Lenart-Lipinska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract. 2013;101(2):194\u2013200.","journal-title":"Diabetes Res Clin Pract"},{"key":"229_CR27","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/srep02767","volume":"3","author":"SQ Liu","year":"2013","unstructured":"Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 2013;3:2767.","journal-title":"Sci Rep"},{"issue":"3","key":"229_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000363031","volume":"34","author":"XM Wang","year":"2014","unstructured":"Wang XM, Song SS, Xiao H, Gao P, Li XJ, Si LY. Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells. Cell Physiol Biochem. 2014;34(3):658\u201371.","journal-title":"Cell Physiol Biochem"},{"issue":"21","key":"229_CR29","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","volume":"131","author":"Z Lin","year":"2015","unstructured":"Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, et al. Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice. Circulation. 2015;131(21):1861\u201371.","journal-title":"Circulation"},{"issue":"9","key":"229_CR30","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1210\/en.2012-1193","volume":"153","author":"J Diaz-Delfin","year":"2012","unstructured":"Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology. 2012;153(9):4238\u201345.","journal-title":"Endocrinology"},{"key":"229_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-015-0190-7","volume":"14","author":"X Zhang","year":"2015","unstructured":"Zhang X, Hu Y, Zeng H, Li L, Zhao J, Zhao J, et al. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol. 2015;14:32.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"229_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1114\/1.121","volume":"26","author":"O Smedby","year":"1998","unstructured":"Smedby O. Geometrical risk factors for atherosclerosis in the femoral artery: a longitudinal angiographic study. Ann Biomed Eng. 1998;26(3):391\u20137.","journal-title":"Ann Biomed Eng"},{"issue":"1","key":"229_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.diabres.2010.03.019","volume":"89","author":"K Eto","year":"2010","unstructured":"Eto K, Tumenbayar B, Nagashima S, Tazoe F, Miyamoto M, Takahashi M, et al. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010;89(1):52\u20137.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"229_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cmet.2008.06.014","volume":"8","author":"C Galman","year":"2008","unstructured":"Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008;8(2):169\u201374.","journal-title":"Cell Metab"},{"issue":"2","key":"229_CR35","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.1210\/jc.2010-1326","volume":"96","author":"H Tyynismaa","year":"2011","unstructured":"Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2011;96(2):E351\u20135.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-015-0229-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0229-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T14:25:16Z","timestamp":1630592716000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-015-0229-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1186\/s12933-015-0229-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,6]]},"assertion":[{"value":"18 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"72"}}